A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial

A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.

Start Date01 Apr 2025

Sponsor / Collaborator

Bir Hospital

CTRI/2024/11/077322

/ Not yet recruitingNot ApplicableIIT

Comparative study of solifenacin as monotherapy versus solifenacin with duloxetine as combination therapy in neurogenic overactive bladder among supra-sacral spinal cord injury patients: An open label randomized clinical trial. - IRB

Start Date05 Dec 2024

Sponsor / Collaborator-

NCT06489951

/ Not yet recruitingNot ApplicableIIT

Efficacy and Safety of Short-term High-dose Vitamin D Supplementation Combined With Standard Behavioral Therapy for the Treatment of Dry Overactive Bladder in Children: a Prospective, Randomized Controlled, Multicentre Clinical Study

The aim of this study is to give children with dry OAB: (1) Standard behavioral therapy combined with classical anticholinergic drugs (Solinaxine), or (2) standard behavioral therapy combined with short-term high-dose exogenous vitamin D supplementation are used to compare the outcomes of lower urinary tract symptoms in children with dry OAB during follow-up. To provide more robust supporting evidence for the broader promotion of short-term high-dose exogenous vitamin D supplements in combination with standard behavioral therapy as an effective treatment for dry OAB treatment in children.

Start Date01 Dec 2024

Sponsor / Collaborator

Children’S Hospital Of Chongqing Medical University

[+2]

100 Clinical Results associated with Solifenacin Succinate

100 Translational Medicine associated with Solifenacin Succinate

100 Patents (Medical) associated with Solifenacin Succinate

869

Literatures (Medical) associated with Solifenacin Succinate

01 Feb 2025·NEUROUROLOGY AND URODYNAMICS

Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns

Article

Author: Enemchukwu, Ekene A. ; S. Burton, Claire ; Gunamany, Susanna ; Syan, Raveen ; Zhang, Chiyuan A. ; Sinclair, Shada ; Mohamud, Hodan

ABSTRACT:

Introduction:

Overactive bladder (OAB) is a chronic condition with significant financial and health‐related consequences. Guidelines and treatment pathways were created to optimize care and provide a clinical framework for diagnosing and managing OAB. However, the impact of these efforts and patterns of medical treatment for OAB are poorly understood. Therefore, we sought to evaluate overall trends in therapy utilization before and after the 2014 American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) OAB guideline amendment and publication of the OAB clinical care pathway in 2016.

Methods:

In this retrospective cohort study, we analyzed data from Optum, a national administrative health and pharmacy claims database, between 2013 and 2018. All adult patients diagnosed with idiopathic OAB were identified by the International Classification of Diseases 9th and 10th Revision codes. Oral OAB therapies were identified using National Drug Codes, while third‐line therapy procedures, onabotulinumtoxinA (BTX), sacral neuromodulation (SNM), and percutaneous tibial nerve stimulation (PTNS), were identified using Current Procedural Terminology (CPT) codes. The study's primary outcome was the annual number of OAB prescriptions filled by pharmacotherapy class and the number of minimally invasive therapies performed during the study period. The secondary outcome was the association between OAB therapy utilization and various clinical and sociodemographic factors. Patterns of care were analyzed from 2013 to 2018, and initial treatment with each therapy was collected, excluding repeat procedures from the analysis.

Results:

1 825 782 patients were included in the study. The mean age was 61.1 ± 16.7 years, and 1 071 420 patients were female (58.7%). The number of new OAB diagnoses increased by 369% from 2013 to 2017. During the 6‐year study period, 347 052 (19%) patients were treated with oral and/or third‐line therapies. The overall number of oral medications prescribed peaked in 2016, followed by a 17% decline between 2016 and 2018. In 2013, the two most prescribed oral medications were oxybutynin (46%) and solifenacin (31.8%). By 2018, mirabegron (18.5%) surpassed solifenacin (16.5%), with oxybutynin still accounting for most prescriptions written (55%). Eighty percent of all initial mirabegron prescriptions were filled by patients over the age of 65. The rate of third‐line therapy procedures almost doubled between 2013 and 2018 (9–17 procedures per 1000 OAB patients, p < 0.001).

Conclusions:

Following the publication of the first OAB guidelines, there was an increase in OAB diagnoses, followed by a decrease in anticholinergic medication use, and a rise in beta‐3 agonist utilization in patients over 65 years old. Additionally, there was greater adoption of third‐line OAB therapies. These trends indicate that OAB therapy guidelines and clinical practice pathways may influence treatment patterns. Given the recent publication of the OAB guidelines, further studies are necessary to assess their impact on therapy utilization patterns.

01 Apr 2025·Journal of Pediatric Urology

Long-term efficacy of Mirabegron-anticholinergic combination in paediatric neurogenic bladder

Article

Author: Clothier, Jo ; Manuele, Riccardo ; Taghizadeh, Arash K ; Page, Anna ; Wright, Anne

INTRODUCTION:

The Mirabegron-anticholinergic (MAC) combination has proven effective as a step-up strategy in managing paediatric neurogenic bladder following anticholinergic medication and botulinum toxin (BTX) therapy. This study assesses the long-term efficacy of MAC in children with neurogenic bladder.

PATIENTS AND METHODS:

A retrospective chart review was conducted from 2015 to 2023, including consecutive paediatric patients receiving Mirabegron (25/50 mg) with an anticholinergic agent (solifenacin 16, tolterodine 7, oxybutynin 7, trospium 1). MAC was started where previous therapy had failed to control bladder pressures. The study cohort had a minimum of 2 years of videourodynamics (VUD) follow-up (2-7 years) and 3.5 years of symptomatic follow-up (2-7 years). All patients used CIC. Efficacy was determined from VUD data, symptom reports, and adverse events (AEs) with upper tract status. Statistical analysis used median values, Friedman's two-way analysis of variance by ranks and Chi-squared testing (p < 0.05).

RESULTS:

The analysis included 31 children (median age at start: 8 years, range: 4-15 years; 12 females) with neurogenic bladder due to myelomeningocele (17), closed spinal dysraphism (11), or spinal cord injury/tumour (3). A minimum of 8 weeks post-MAC therapy, significant improvements were observed in VUD parameters of: bladder capacity, compliance, and maximum detrusor pressure. These improvements were sustained at final VUD follow-up (median 33 months) in 21 patients (Summary Table). However, 9 patients who showed initial VUD improvement at median 5 months lost the effect by median 27 months, with 4 non-adherent patients and 5 with lower initial bladder compliance. Initial symptom improvement occurred in 25 patients, sustained for a median of 43 months (range: 23-85) in 19 patients. Adverse events were minimal (constipation, fatigue, and UTI reported in one patient each). No significant changes in blood pressure or upper tract status were observed.

CONCLUSION:

MAC combination effectively manages paediatric neurogenic bladder resistant to AC and BTX therapy. The VUD benefits (present in 77.8 %) and symptom benefits (present in 61 %) are maintained and ongoing for a significant period (median 33 and 43 months respectively) when commenced before significant loss of compliance. MAC presents a promising long-term treatment option for the paediatric neurogenic bladder.

31 Dec 2024·International Neurourology Journal

Efficacy of Combined Therapy With Silodosin and Solifenacin in Females With Overactive Bladder

Article

Author: Bae, Jae Hyun ; Park, Jae Young ; Tae, Bum Sik ; Jeon, Byeong Jo ; Chang, Hyun Kyung ; Yoon, Duck Ki

Purpose: We aimed to assess the clinical efficacy and safety of combining silodosin and solifenacin for overactive bladder (OAB) in females.Methods: A retrospective analysis of 586 females with OAB was conducted. Patients received either combination therapy (silodosin 8 mg + solifenacin 5 mg) or monotherapy (solifenacin 5 mg) for 12 weeks. Baseline and follow-up assessments included the overactive bladder symptom score (OABSS), International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), voided volume (VV), and postvoid residual urine volume (PVR).Results: Overall, 287 and 299 patients received combination therapy and monotherapy respectively. Both groups experienced significant improvements in OABSS and total IPSS after 12 weeks. The combination therapy group demonstrated a greater improvement in QoL compared to the monotherapy group (P=0.031). No significant differences were observed in Qmax or VV between the groups. However, the combination therapy group showed a significant reduction in PVR compared to the monotherapy group (P<0.001).Conclusions: Combining silodosin with solifenacin significantly improved OAB symptoms and QoL in females. This combination therapy was particularly effective in reducing postvoid residual volume compared to solifenacin alone. These findings suggest that adding an alpha-blocker to antimuscarinic therapy can enhance OAB management and patient satisfaction.

News (Medical) associated with Solifenacin Succinate

04 Dec 2024

·www.drugs.com

Overactive Bladder Diagnoses Increased After Guideline Publication

WEDNESDAY, Dec. 4, 2024 -- An increase in overactive bladder (OAB) diagnoses was seen following publication of the first OAB guideline, and the rate of third-line therapy procedures also increased, according to a study published online Nov. 19 in Neurourology & Urodynamics . Hodan Mohamud, from the University of Toronto, and colleagues conducted a retrospective cohort study to examine trends in therapy utilization before and after the 2014 American Urological Association/Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction OAB guideline amendment and publication of a clinical care pathway in 2016. Patterns of care were assessed from 2013 to 2018. The study included 1,825,782 patients (mean age, 61.1 ± 16.7 years). From 2013 to 2017, the researchers found a 369 percent increase in the number of new OAB diagnoses. Nineteen percent of patients were treated with oral and/or third-line therapies during the six-year study period. The number of oral medications prescribed peaked in 2016, then decreased 17 percent by 2018. The two most prescribed oral medications in 2013 were oxybutynin and solifenacin (46.0 and 31.8 percent, respectively). Mirabegron surpassed solifenacin by 2018 (18.5 versus 16.5 percent), while oxybutynin still accounted for most prescriptions (55 percent). Patients older than 65 years of age filled 80 percent of all initial mirabegron prescriptions. From 2013 to 2018, the rate of third-line therapy procedures nearly doubled (nine to 17 per 1,000 OAB patients). "These trends suggest that OAB therapy guidelines and clinical practice pathways may influence treatment patterns," the authors write. One author disclosed ties to the pharmaceutical industry.

Clinical Result

26 Jun 2023

·www.adamed.com

Adamed Launches New Polish Drug to Effectively Support Patients with Urological Diseases

Adamed Pharma is launching its latest combination drug containing an innovative composition of solifenacin and tamsulosin, which is an important addition to the therapies available in the field of pharmacotherapy for urinary tract complaints in men caused by benign prostatic hyperplasia. Adamed Pharma has spent more than five years developing and implementing the drug, which responds to the needs of patients around the world. Adamed Pharma began development of the combination product (modified-release tablets containing solifenacin succinate + tamsulosin hydrochloride) in July 2018. It was an in-depth analysis of patient needs for urological diseases that influenced the decision to develop the drug for such a broad patient population. Indeed, benign prostatic hyperplasia is often a very important life problem for men, negatively affecting both professional and private life. Given the widespread epidemiology of prostatic hyperplasia diseases, the composition of solifenacin with tamsulosin in oral tablet form is the subject of an international patent application of Adamed Pharma (WO2022117594). Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, the small gland that surrounds the male urethra. Benign prostatic hyperplasia is among the most common urological diseases in men and is age-related. According to demographic forecasts by Statistics Poland (GUS), in Poland in 2050, the share of people over the age of 65 will be as high as 32.7%[i], so in the not-too-distant future, many men will live to an age when they develop symptoms of BPH. More than 70% of men over the age of 40 are affected by lower urinary tract complaints.[ii] The latest analysis – conducted as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 – covered 204 countries in the years 2000-2019. It was revealed that there were 94.0 million cases of benign prostatic hyperplasia worldwide in 2019, up from 51.1 million cases in 2000 (70.5% increase in incidence). In Eastern Europe, by contrast, the percentage change in the incidence of BPH was 19.3%, with 49.9% in Poland.[iii]. “We are proud of the results we have achieved in the development of our new value-added product and the process of its launch in the global market. Thanks to the work of the Adamed Research Team and the commitment of our partners, we are introducing a therapy which has a significant impact on the lives and health of patients around the world,” says Sylwia Berdzik-Kalarus, Member of the Management Board of Adamed Pharma S.A., Director of Commercial Affairsand Business Development. The partner involved financially in the development and implementation of this Adamed product is Adalvo, a leading B2B pharmaceutical company in Europe. “Adamed’s mission is to respond to the key challenges of contemporary medicine. As a company founded and still run by doctors, Adamed has always put the well-being of patients first. That’s why we appreciate the cooperation between Adamed and Adalvo, which is based on deep understanding of patients, their needs and expectations,” she adds. Adamed Pharma’s R&D teams continue their R&D efforts to be able to provide patients with new innovative therapies in the future. More than 50 development projects are currently under way at various stages. [i] Polish Agency for Enterprise Development (PARP): Aging of the Population – A Challenge for the Labour Market, Activation of 50+ Employees; https://www.parp.gov.pl/storage/publications/pdf/Starzenie_sie_spoleczenstw.pdf [ii] Coyne K.S., Sexton C.C., Thompson C.L. et al.: The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. Bju International. 2009;104(3):352–360 [iii] Awedew A.F., Han H., Abbasi B. et al.: The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019, The Lancet Healthy Longevity, Volume 3, Issue 11, 2022, Pages e754-e776, ISSN 2666-7568, https://doi-org.libproxy1.nus.edu.sg/10.1016/S2666-7568(22)00213-6

Drug Approval

05 Dec 2022

·www.businesswire.com

$4.2 Billion Overactive Bladder Treatment (OAB) Markets - Global Forecasts to 2027: Growing R&D Investments and the Launch of Novel Therapies in the Coming Years - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027" report has been added to ResearchAndMarkets.com's offering. The global overactive bladder treatment market is projected to reach USD 4.2 billion by 2027 from USD 3.5 billion in 2022, at a CAGR of 3.6% Rising prevalence of overactive bladder across the globe coupled with rising awareness about treatment options available is driving the growth of the market. Additionally, use of neuromodulation techniques for the treatment of OAB is further expected to have a significant positive impact. The adoption of novel treatments and the launch of new drugs for OAB treatment are also likely to support market growth in the coming years. Mirabegron segment dominates the overactive bladder (OAB) treatment market in 2021. Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing to the lesser side-effects associated with this drug compared to other drug classes available in the market. Furthermore, neuromodulation segment is expected to grow at faster pace owing to launch of new SNM & PTNS for OAB in market. The idiopathic overactive bladder segment will witness the highest growth in overactive bladder treatment market during the forecast period. Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for the treatment. North America held dominant share in 2021. In 2021, North America accounted for the major share in the OAB treatment market. North America holds majority of the key market players leading to maturity of OAB treatment market in this region. Furthermore, favorable reimbursement policies in US is one of the leading factor projecting market growth in North America. Competitive landscape The prominent players in this market are Astellas Pharma Inc. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (US), Medtronic Plc (Ireland), AbbVie Inc. (US), Viatris Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Johnson & Johnson Services, Inc. (US), and Endo Pharmaceuticals Inc. (Ireland). Market Dynamics Market Drivers Rising Prevalence of Overactive Bladder Syndrome Rapidly Aging Population and Subsequent Rise in Incidence of Diseases Characterized by Oab Development and Use of Innovative Intravesical Therapies Growing R&D Investments and the Launch of Novel Therapies in the Coming Years Market Restraints Frequent Product Recalls Increased Side-Effects of Anticholinergic Drugs Market Opportunities Novel Treatments, Robust Pipelines, and Patent Cliff of Certain Drugs Market Challenges Social Stigma and Lack of Awareness About OAB Companies mentioned: Abbvie Inc Ajanta Pharma Altherx Pharmaceuticals Amneal Pharmaceuticals LLC Apotex Inc Astellas Pharma Inc Bayer Ag Endo Pharmaceuticals Inc Glenmark Granules India Limited Hisamitsu Pharmaceutical Co Inc Hugel, Inc Intas Pharmaceuticals Ltd Johnson & Johnson Services, Inc Laborie Lupin Macleods Pharmaceuticals Ltd Medtronic Medytox Pfizer Inc Sun Pharmaceutical Industries Ltd Taiho Pharmaceutical Co Ltd Teva Pharmaceutical Industries Ltd Urovant Sciences Viatris Inc For more information about this report visit https://www.researchandmarkets.com/r/2n1a4y About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 Deals associated with Solifenacin Succinate

External Link

KEGG	Wiki	ATC	Drug Bank
D01269	Solifenacin Succinate	G04BD08	DB01591

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neurogenic detrusor overactivity	United States	Astellas Pharma US, Inc.	26 May 2020
Urinary Bladder, Overactive	Japan	Astellas Pharma, Inc.	20 Apr 2006
Pollakisuria	United States	Astellas Pharma US, Inc.	19 Nov 2004
Urinary Incontinence, Urge	United States	Astellas Pharma US, Inc.	19 Nov 2004
Overactive bladder syndrome	Netherlands	Astellas Pharma Europe BV	08 Jun 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urinary urgency	Phase 3	Belgium	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	Czechia	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	Egypt	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	France	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	Germany	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	Greece	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	Hungary	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	Italy	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	Poland	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	Portugal	Astellas Pharma, Inc.	01 Apr 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03149809 (BOSS PD, CTgov)	Phase 3	Urinary Bladder, Overactive \| Parkinson Disease	77	Pelvic floor muscle exercise-based behavioral therapy (Behavioral Therapy)	vznohzgpzq(szskkkuday) = ggcbgrtadg hfwwrhygef (xqumdpwdrz, 2.0) View more	-	24 Sep 2024
				solifenacin (Drug Therapy)	vznohzgpzq(szskkkuday) = hujjrjrzzs hfwwrhygef (xqumdpwdrz, 2.4) View more
NCT04090190 (CTgov)	Phase 4	Urinary Incontinence \| Urinary urgency \| Inflammation	20	Oxybutynin+Tolterodine+Trospium+Solifenacin+Fesoterodine	sknmwdbzor(udacfaoysb) = hxlsalgsoc cxmptfweve (ypqbhfekam, fvulhgexdu - pjtnceqxmt) View more	-	03 Oct 2022
NCT01981954 \| NCT01565694 (Pubmed \| J Pediatr Urol)	Phase 3	Neurogenic detrusor overactivity	-	Solifenacin oral suspension	hznbumpjsi(urtcyykase) = ftsveixftt nkubgzmuwe (zdegawcdnj )	-	01 Apr 2020
NCT01565694 (CTgov)	Phase 3	Neurogenic detrusor overactivity	76	Solifenacin succinate	yqaufqzods(pbfqqbgnit) = vakahudfcx pgabtkayax (vdtbsakqme, 107.7) View more	-	06 May 2019
NCT02549196 (CPC-12, CTgov)	Phase 2	Dystocia \| Dementia due to Alzheimer's disease (disorder)	28	Donepezil+Solifenacin (Cohort 1)	ziaxsfniho = vjntujxzyv elqchbytzj (uiyumoiuoy, pjtzeagjqg - xabtvxftpc) View more	-	05 Mar 2019
				Donepezil+Solifenacin (Cohort 2)	ziaxsfniho = fiqlbbnapa elqchbytzj (uiyumoiuoy, puxbihlucl - pvwwpvhnxh) View more
NCT02294396 (CTgov)	Phase 4	Urinary Bladder, Overactive	649	Mirabegron tablet+Solifenacin tablet (Mirabegron + Solifenacin)	fcfqzuukpc = mirsrtpvyt dthsinfzsq (pvhiyywhhp, muyblqygyz - pryirgomdz) View more	-	24 Dec 2018
				Mirabegron tablet+Propiverine tablet (Mirabegron + Propiverine)	fcfqzuukpc = vyqygdjrzi dthsinfzsq (pvhiyywhhp, puuntmeyib - ykuedwefod) View more
NCT01981954 (CTgov)	Phase 3	Neurogenic detrusor overactivity	23	Solifenacin succinate	unpljayfmw(etszpmkfjh) = zwndzlzhca gpkehiwtbo (drbrqtrwyw, 35.9) View more	-	21 Jun 2018
NCT01972841 (SYNERGY, CTgov)	Phase 3	Urinary Bladder, Overactive	3,527	placebo (Placebo)	buuxegczbi(lkgdgwtdgy) = rybwqnhyre nzatcaenrr (igxwvsxplu, 0.10) View more	-	12 Jun 2018
				Mirabegron (Mirabegron 25 mg)	buuxegczbi(lkgdgwtdgy) = rvzkhpmnzt nzatcaenrr (igxwvsxplu, 0.10) View more
NCT02045862 (SYNERGY II, CTgov)	Phase 3	Urinary Bladder, Overactive	1,829	Placebo to match solifenacin+Mirabegron (Mirabegron 50 mg)	gkhyhmxfic = pbsmihqeth fegdgcwrhi (dnmhoruqip, zujztkwpjn - qmhbzlegti) View more	-	06 Jun 2018
				Placebo to match mirabegron+Solifenacin succinate (Solifenacin 5 mg)	gkhyhmxfic = kqroouogqy fegdgcwrhi (dnmhoruqip, glbnzhmpdj - oizcdyvhcl) View more
NCT01486706 (Pubmed \| Low Urin Tract Symptoms)	Phase 2/3	Urinary Bladder, Overactive	94	Placebo	psdtccxibi(cdbcqosgfu): AMD = -1.179 (95% CI, -1.98 to -0.38) View more	Positive	01 May 2018
				Gabapentin

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Solifenacin Succinate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation